MedTrace Logo

Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT

NCT06319131 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2024-03-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the comparative effectiveness of nadroparin versus transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory asymptomatic portal vein thrombosis using a design of a multicenter, randomized controlled trial

Conditions

  • Portal Vein Thrombosis

Interventions

PROCEDURE

TIPS

Using the transjugular approach, TIPS was created under local anesthesia. The first branch of the left or right portal vein (PV) was punctured by RUPS-100 set guided by digital subtraction angiography. After successful access into PV, direct portography was performed and all visible varices and/or concurrent spontaneous portosystemic shunts (SPSS) were embolized with coils and n-butyl cyanoacrylate. A polytetrafluoroethylene-covered stent (Viatorr Endoprosthesis, GORE and Associates, Flagstaff, Arizona, USA) with a diameter of 8 mm was implanted and fully dilated.

DRUG

Nadroparin

Nadroparin calcium will be subcutaneously injected with the dose of 85IU/kg q12h

Sponsors & Collaborators

  • Shanghai 6th People's Hospital

    collaborator OTHER

  • ShuGuang Hospital

    collaborator OTHER

  • Tongji Hospital

    collaborator OTHER

  • Renmin Hospital of Wuhan University

    collaborator OTHER

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Jian Wang, MD · Shanghai Zhongshan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2025-05-30
Completion
2026-05-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06319131 on ClinicalTrials.gov